

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6221352/publications.pdf>

Version: 2024-02-01

535
papers

26,984
citations

5574

82
h-index

10734

138
g-index

538
all docs

538
docs citations

538
times ranked

18894
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the Impact of Provider Training and Perceived Barriers on the Provision of Spiritual Care: a Mixed Methods Study. <i>Journal of Cancer Education</i> , 2023, 38, 301-308.	1.3	3
2	Surgeon Strategies to Patient-Centered Decision-making in Cancer Care: Validation and Applications of a Conceptual Model. <i>Journal of Cancer Education</i> , 2022, 37, 1719-1726.	1.3	1
3	Rural hospitals are not associated with worse postoperative outcomes for colon cancer surgery. <i>Journal of Rural Health</i> , 2022, 38, 650-659.	2.9	10
4	The impact of social vulnerability subthemes on postoperative outcomes differs by racial/ethnic minority status. <i>American Journal of Surgery</i> , 2022, 223, 353-359.	1.8	9
5	The Influence of Patient and Provider Religious and Spiritual Beliefs on Treatment Decision Making in the Cancer Care Context. <i>Medical Decision Making</i> , 2022, 42, 125-134.	2.4	5
6	Patient Perspectives on Defining Textbook Outcomes Following Major Abdominal Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 197-205.	1.7	11
7	Timing and Severity of Postoperative Complications and Associated 30-Day Mortality Following Hepatic Resection: a National Surgical Quality Improvement Project Study. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 314-322.	1.7	2
8	Assessment of Textbook Outcome After Surgery for Stage I/II Non-small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2022, 34, 1351-1359.	0.6	10
9	Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 315-324.	1.5	16
10	Association of Community Economic Distress and Breast and Colorectal Cancer Screening, Incidence, and Mortality Rates Among US Counties. <i>Annals of Surgical Oncology</i> , 2022, 29, 837-848.	1.5	7
11	Social vulnerability and fragmentation of postoperative surgical care among patients undergoing hepatopancreatic surgery. <i>Surgery</i> , 2022, 171, 1043-1050.	1.9	8
12	Development of a Prognostic Nomogram and Nomogram Software Application Tool to Predict Overall Survival and Disease-Free Survival After Curative-Intent Gastrectomy for Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 1220-1229.	1.5	8
13	Trends in Textbook Outcomes over Time: Are Optimal Outcomes Following Complex Gastrointestinal Surgery for Cancer Increasing?. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 50-59.	1.7	18
14	Does the Volume-Outcome Association in Pancreas Cancer Surgery Justify Regionalization of Care? A Review of Current Controversies. <i>Annals of Surgical Oncology</i> , 2022, 29, 1257-1268.	1.5	18
15	The role of religion and spirituality in cancer care: An umbrella review of the literature. <i>Surgical Oncology</i> , 2022, 42, 101389.	1.6	15
16	Is Hospital Occupancy Rate Associated With Postoperative Outcomes Among Patients Undergoing Hepatopancreatic Surgery?. <i>Annals of Surgery</i> , 2022, 276, 153-158.	4.2	8
17	Textbook oncologic outcome in pancreaticoduodenectomy: Do regionalization efforts make sense?. <i>Journal of Surgical Oncology</i> , 2022, 125, 414-424.	1.7	11
18	Implications of intensive care unit admissions among medicare beneficiaries following resection of pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 405-413.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Surgical management of intrahepatic cholangiocarcinoma. Expert Review of Anticancer Therapy, 2022, 22, 27-38.	2.4	16
20	Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice. Journal of Gastrointestinal Surgery, 2022, 26, 1021-1029.	1.7	8
21	Impact of hospital quality on surgical outcomes in patients with high social vulnerability: Association of textbook outcomes and social vulnerability by hospital quality. Surgery, 2022, 171, 1612-1618.	1.9	12
22	Social Vulnerability Subtheme Analysis Improves Perioperative Risk Stratification in Hepatopancreatic Surgery. Journal of Gastrointestinal Surgery, 2022, 26, 1171-1177.	1.7	9
23	Does Extended Lymphadenectomy Help in Pancreatic Cancer?. Annals of Surgical Oncology, 2022, 29, 2131.	1.5	3
24	Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. British Journal of Surgery, 2022, 109, 610-616.	0.3	13
25	Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Annals of Surgical Oncology, 2022, 29, 4291-4303.	1.5	23
26	Intersectionality in cancer care: A systematic review of current research and future directions. Psycho-Oncology, 2022, 31, 705-716.	2.3	27
27	Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Review of Anticancer Therapy, 2022, 22, 297-306.	2.4	3
28	Nontumor related risk score: A new tool to improve prediction of prognosis after hepatectomy for colorectal liver metastases. Surgery, 2022, 171, 1580-1587.	1.9	2
29	ASO Author Reflections: Impact of Tumor Necrosis on Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, 29, 2975-2976.	1.5	1
30	Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, 29, 4326-4334.	1.5	7
31	Machine Learning Approach to Stratifying Prognosis Relative to Tumor Burden after Resection of Colorectal Liver Metastases: An International Cohort Analysis. Journal of the American College of Surgeons, 2022, 234, 504-513.	0.5	1
32	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. Journal of Surgical Oncology, 2022, 125, 621-630.	1.7	9
33	ASO Author Reflections: The Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
34	Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 5177-5185.	1.5	4
35	Association of Preoperative Body Mass Index with Surgical Textbook Outcomes Following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Study of 1206 Patients. Annals of Surgical Oncology, 2022, 29, 4278-4286.	1.5	14
36	Financial Impact of Out-of-Pocket Costs Among Patients Undergoing Resection for Colorectal Carcinoma. Annals of Surgical Oncology, 2022, 29, 5387-5397.	1.5	6

#	ARTICLE	IF	CITATIONS
37	ASO Author Reflections: Association of County-level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment Among Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
38	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2018.	3.7	15
39	Impact of neighborhood characteristics on textbook outcome following major surgery. <i>American Journal of Surgery</i> , 2022, 224, 959-964.	1.8	2
40	The Impact of Tumor Burden on Survival Differs by Morphological Subtype Among Patients Diagnosed with Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1764-1765.	1.7	2
41	Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 2208.	3.7	10
42	Surgical outcomes of gastroenteropancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. <i>Journal of Surgical Oncology</i> , 2022, 126, 689-697.	1.7	4
43	Using Machine Learning to Preoperatively Stratify Prognosis among Patients with Gallbladder Cancer: A Multi-Institutional Analysis. <i>Hpb</i> , 2022, , .	0.3	1
44	Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1697-1704.	1.7	3
45	Short- and long-term outcomes following robotic and open resection for intrahepatic cholangiocarcinoma: A national cohort study. <i>Surgical Oncology</i> , 2022, 43, 101790.	1.6	4
46	Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium. <i>Annals of Surgical Oncology</i> , 2022, 29, 7605-7614.	1.5	7
47	Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping. <i>Cancers</i> , 2022, 14, 3284.	3.7	11
48	Intrapersonal Factors Impact Advance Care Planning Among Cancer Patients. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 907-913.	1.4	8
49	Utilization of High-Volume Hospitals for High-Risk Cancer Surgery in California Following Medicaid Expansion. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1875-1884.	1.7	6
50	County-Level Variation in Utilization of Surgical Resection for Early-Stage Hepatopancreatic Cancer Among Medicare Beneficiaries in the USA. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1736-1744.	1.7	3
51	Refusal of Surgery Among Patients with Early-Stage Hepato-Pancreato-Biliary Cancers: Predictive Factors and Outcomes. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1573-1575.	1.7	2
52	Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 155-161.	1.7	23
53	Comparison of lymph node evaluation and yield among patients undergoing open and minimally invasive surgery for gallbladder adenocarcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 2223-2228.	2.4	11
54	Do Religious/Spiritual Preferences and Needs of Cancer Patients Vary Based on Clinical- and Treatment-Level Factors?. <i>Annals of Surgical Oncology</i> , 2021, 28, 59-66.	1.5	2

#	ARTICLE	IF	CITATIONS
55	Comparing Surgeon Approaches to Patient-Centered Cancer Care Using Vignette Methodology. Journal of Gastrointestinal Surgery, 2021, 25, 1307-1315.	1.7	1
56	The beliefs of cancer care providers regarding the role of religion and spirituality within the clinical encounter. Supportive Care in Cancer, 2021, 29, 909-915.	2.2	10
57	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. Neuroendocrinology, 2021, 111, 129-138.	2.5	12
58	Quality of Care Among Medicare Patients Undergoing Pancreatic Surgery: Safety Grade, Magnet Recognition, and Leapfrog Minimum Volume Standards—Which Quality Benchmark Matters?. Journal of Gastrointestinal Surgery, 2021, 25, 269-277.	1.7	19
59	Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis. Journal of Gastrointestinal Surgery, 2021, 25, 125-133.	1.7	38
60	ASO Author Reflections: How Does Social Vulnerability Impact Hospice Utilization Among Patients Undergoing Cancer Surgery?. Annals of Surgical Oncology, 2021, 28, 1927-1928.	1.5	0
61	Impact of time-to-surgery on outcomes of patients undergoing curative-intent liver resection for BCLC A and B hepatocellular carcinoma. Journal of Surgical Oncology, 2021, 123, 381-388.	1.7	8
62	Association of County-Level Social Vulnerability with Elective Versus Non-elective Colorectal Surgery. Journal of Gastrointestinal Surgery, 2021, 25, 786-794.	1.7	54
63	Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 1156-1163.	1.7	20
64	Association of Neighborhood Characteristics with Utilization of High-Volume Hospitals Among Patients Undergoing High-Risk Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 617-631.	1.5	42
65	Prediction of tumor recurrence by α -fetoprotein model after curative resection for hepatocellular carcinoma. European Journal of Surgical Oncology, 2021, 47, 660-666.	1.0	20
66	Moving Toward a More Informed Approach to Risk Stratification of Patients: Comments on Seror et al. CT-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related HCC. Annals of Surgical Oncology, 2021, 28, 24-26.	1.5	0
67	Tumor Necrosis Impacts Prognosis of Patients Undergoing Curative-Intent Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 797-805.	1.5	28
68	Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?. Annals of Surgical Oncology, 2021, 28, 1970-1978.	1.5	30
69	Inter-surgeon variability is associated with likelihood to undergo minimally invasive hepatectomy and postoperative mortality. Hpb, 2021, 23, 840-846.	0.3	1
70	The association of Hospital Medicare beneficiary payer-mix, national quality rankings and outcomes following hepatopancreatic surgery. American Journal of Surgery, 2021, 221, 492-496.	1.8	2
71	Assessment of hospital quality and safety standards among Medicare beneficiaries undergoing surgery for cancer. Surgery, 2021, 169, 573-579.	1.9	4
72	Race/Ethnicity and County-Level Social Vulnerability Impact Hospice Utilization Among Patients Undergoing Cancer Surgery. Annals of Surgical Oncology, 2021, 28, 1918-1926.	1.5	26

#	ARTICLE	IF	CITATIONS
73	Sex-based differences in time to surgical care among pancreatic cancer patients: A national study of Medicare beneficiaries. <i>Journal of Surgical Oncology</i> , 2021, 123, 236-244.	1.7	11
74	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. <i>Surgical Oncology</i> , 2021, 37, 101492.	1.6	15
75	Insurance status and high-volume surgical cancer: Access to high-quality cancer care. <i>Cancer</i> , 2021, 127, 507-509.	4.1	2
76	The religious/spiritual beliefs and needs of cancer survivors who underwent cancer-directed surgery. <i>Palliative and Supportive Care</i> , 2021, 19, 175-181.	1.0	4
77	ASO Visual Abstract: Defining and Predicting Early Recurrence After Resection for Gallbladder Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 426-427.	1.5	0
78	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. <i>Hpb</i> , 2021, 23, 25-36.	0.3	16
79	ASO Author Reflections: Validated Prediction Model of Early Recurrence after Resection for Gallbladder Cancer: Identifying a Subset of Patients Who May be Better Served with Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 428-429.	1.5	1
80	Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 417-425.	1.5	21
81	Characterizing Pastoral Care Utilization by Cancer Patients. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 758-765.	1.4	3
82	Assessment of Cancer Center Variation in Textbook Oncologic Outcomes Following Colectomy for Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 775-785.	1.7	26
83	Trends in the Geospatial Distribution of Inpatient Adult Surgical Services across the United States. <i>Annals of Surgery</i> , 2021, 273, 121-127.	4.2	49
84	ASO Author Reflections: Tumor Burden in Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 1979-1980.	1.5	0
85	Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 978-985.	1.7	7
86	Role of Node Dissection in Pancreatic Tumor Resection. <i>Annals of Surgical Oncology</i> , 2021, 28, 2374-2381.	1.5	13
87	Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: Pancreaticoduodenectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 6965-6969.	1.5	4
88	Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 747.	3.7	26
89	Provision of supportive spiritual care for hepatopancreatic cancer patients: an unmet need?. <i>Hpb</i> , 2021, 23, 1400-1409.	0.3	5
90	End-of-Life Hospice Use and Medicare Expenditures Among Patients Dying of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 5414-5422.	1.5	10

#	ARTICLE	IF	CITATIONS
91	Conditional Recurrence-Free Survival for Patients with Gallbladder Cancer: A Personalized Resource for Patients and Providers. <i>Annals of Surgical Oncology</i> , 2021, 28, 2436-2437.	1.5	0
92	Impact of Metabolic Syndrome on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2545-2552.	1.7	6
93	Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough?. <i>Journal of Surgical Oncology</i> , 2021, 123, 1568-1577.	1.7	3
94	Association of County-Level Vulnerability, Patient-Level Race/Ethnicity, and Receipt of Surgery for Early-Stage Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2021, 156, 197.	4.3	41
95	Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. <i>Journal of Surgical Oncology</i> , 2021, 123, 1558-1567.	1.7	11
96	ASO Author Reflections: Development and Validation of Distal Cholangiocarcinoma Early Recurrence (DICER) Score: Results from the US Extrahepatic Biliary Malignancy Consortium. <i>Annals of Surgical Oncology</i> , 2021, 28, 4214-4215.	1.5	4
97	Recurrence of Non-functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model. <i>World Journal of Surgery</i> , 2021, 45, 2134-2141.	1.6	2
98	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. <i>Hpb</i> , 2021, 23, 413-421.	0.3	18
99	Prognostication in hepatocellular carcinoma: is it a burden or a ticket?. <i>British Journal of Surgery</i> , 2021, 108, 337-339.	0.3	5
100	Association of social vulnerability with the use of high-volume and Magnet recognition hospitals for hepatopancreatic cancer surgery. <i>Surgery</i> , 2021, 170, 571-578.	1.9	21
101	Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2021, 23, 1456-1466.	0.3	10
102	Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4205-4213.	1.5	19
103	Association of Depression with In-Patient and Post-Discharge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6525-6534.	1.5	10
104	ASO Author Reflections: Association of Depression with In-Patient and Post-Discharge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6535-6536.	1.5	2
105	High Social Vulnerability and "Textbook Outcomes" after Cancer Operation. <i>Journal of the American College of Surgeons</i> , 2021, 232, 351-359.	0.5	95
106	Trends in Discharge Disposition Following Hepatectomy for Hepatocellular Carcinoma Among Medicare Beneficiaries. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 2842-2850.	1.7	2
107	Impact of Race/Ethnicity and County-Level Vulnerability on Receipt of Surgery Among Older Medicare Beneficiaries With the Diagnosis of Early Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6309-6316.	1.5	30
108	ASO Author Reflections: Impact of Residential Racial Integration on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Resection for Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7575-7576.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status. <i>Journal of the American College of Surgeons</i> , 2021, 232, 590-598.	0.5	14
110	ASO Author Reflections: County-Level Social Vulnerability Associated with Disparities in Pancreatic Cancer Treatment, Especially among Patients from Racial and Ethnic Minorities. <i>Annals of Surgical Oncology</i> , 2021, 28, 6317-6318.	1.5	1
111	Liver metastases. <i>Nature Reviews Disease Primers</i> , 2021, 7, 27.	30.5	190
112	Impact of Residential Racial Integration on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Resection for Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 7566-7574.	1.5	11
113	Serum α -Fetoprotein Levels at Time of Recurrence Predict Post-Recurrence Outcomes Following Resection of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7673-7683.	1.5	14
114	ASO Author Reflections: AFP Levels at the Time of Recurrence Predict Post-recurrence Outcomes Irrespective of Modality Used to Treat Recurrence. <i>Annals of Surgical Oncology</i> , 2021, 28, 7684-7685.	1.5	0
115	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. <i>Cancers</i> , 2021, 13, 2242.	3.7	6
116	Hepatopancreatic Surgery in the Rural United States: Variation in Outcomes at Critical Access Hospitals. <i>Journal of Surgical Research</i> , 2021, 261, 123-129.	1.6	4
117	Disparities in NCCN Guideline-Compliant Care for Resectable Cholangiocarcinoma at Minority-Serving Versus Non-Minority-Serving Hospitals. <i>Annals of Surgical Oncology</i> , 2021, 28, 8162-8171.	1.5	16
118	ASO Author Reflections: Multi-institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7634-7635.	1.5	1
119	ASO Visual Abstract: Association of Depression with In-Patient and Postdischarge Disposition and Expenditures Among Medicare Beneficiaries Undergoing Resection for Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 429-429.	1.5	2
120	Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 7624-7633.	1.5	4
121	Assessment of Magnet status and Textbook Outcomes among medicare beneficiaries undergoing hepato-pancreatic surgery for cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 334-342.	1.7	7
122	ASO Author Reflections: Minority-Serving Hospitals are Associated with Lower Likelihood of Providing NCCN Guideline Compliant Care to Patients with Resectable Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 8172-8173.	1.5	0
123	Profiles in social vulnerability: The association of social determinants of health with postoperative surgical outcomes. <i>Surgery</i> , 2021, 170, 1777-1784.	1.9	59
124	Association of County-Level Racial Diversity and Likelihood of a Textbook Outcome Following Pancreas Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 8076-8084.	1.5	14
125	Letter to the Editor: Does Multiple Intrahepatic Cholangiocarcinoma Worsen Prognosis as “M1a” Stage?. <i>Hepatology</i> , 2021, 74, 1128-1128.	7.3	3
126	ASO Author Reflections: County-Level Racial Diversity is Associated with Textbook Outcomes for Pancreatic Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 8085-8086.	1.5	0

#	ARTICLE	IF	CITATIONS
127	Editorial: Enhanced Recovery after Surgery Pathways: Improving the Perioperative Experience and Outcomes of Cancer Surgery Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6929-6931.	1.5	0
128	Patient Social Vulnerability and Hospital Community Racial/Ethnic Integration: Do All Patients Undergoing Pancreatectomy Receive the Same Care Across Hospitals?. <i>Annals of Surgery</i> , 2021, 274, 508-515.	4.2	11
129	Intersection of social vulnerability and residential diversity: Postoperative outcomes following resection of lung and colon cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 886-893.	1.7	24
130	Variation in outcomes across surgeons meeting the Leapfrog volume standard for complex oncologic surgery. <i>Cancer</i> , 2021, 127, 4059-4071.	4.1	10
131	Optimal hepatic surgery: Are we making progress in North America?. <i>Surgery</i> , 2021, 170, 1741-1748.	1.9	8
132	Trends and outcomes of simultaneous versus staged resection of synchronous colorectal cancer and colorectal liver metastases. <i>Surgery</i> , 2021, 170, 160-166.	1.9	22
133	Marginalized patient identities and the patient-physician relationship in the cancer care context: a systematic scoping review. <i>Supportive Care in Cancer</i> , 2021, 29, 7195-7207.	2.2	20
134	Impact of Perioperative Thromboembolic Complications on Future Long-term Risk of Venous Thromboembolism among Medicare Beneficiaries Undergoing Complex Gastrointestinal Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 3064-3073.	1.7	1
135	Geographic Disparities in Oncologic Treatment and Outcomes: The Urbanâ€”Rural Divide. <i>Annals of Surgical Oncology</i> , 2021, 28, 8011-8013.	1.5	4
136	Impact of Tumor Burden Score on Conditional Survival after Curativeâ€”Intent Resection for Hepatocellular Carcinoma: A Multiâ€”Institutional Analysis. <i>World Journal of Surgery</i> , 2021, 45, 3438-3448.	1.6	20
137	The State of Immunotherapy in Hepatobiliary Cancers. <i>Cells</i> , 2021, 10, 2096.	4.1	18
138	ASO Author Reflections: Postoperative Infectious Complications Worsen Long-Term Survival After Curative-Intent Resection for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	0
139	State-of-the-art surgery for hepatocellular carcinoma. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 2151-2162.	1.9	12
140	Survival Benefit of Primary Tumor Resection Among Elderly Patients with Pancreatic Neuroendocrine Tumors. <i>World Journal of Surgery</i> , 2021, 45, 3643-3651.	1.6	9
141	Is Textbook Oncologic Outcome a Valid Hospital-Quality Metric after High-Risk Surgical Oncology Procedures?. <i>Annals of Surgical Oncology</i> , 2021, 28, 8028-8045.	1.5	30
142	Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 515-517.	1.5	1
143	Pancreatic neuroendocrine tumours: conservative versus surgical management. <i>British Journal of Surgery</i> , 2021, 108, 1267-1269.	0.3	3
144	ASO Author Reflections: Understanding the Broader Implications of the Volumeâ€”Outcome Impact on Pancreas Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	0

#	ARTICLE	IF	CITATIONS
145	Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. American Journal of Surgery, 2021, 222, 570-576.	1.8	0
146	Does minimally invasive pancreaticoduodenectomy increase the chance of a textbook oncologic outcome?. Surgery, 2021, 170, 880-888.	1.9	11
147	Geospatial Inefficiencies Associated With Digital Replantations at High-Volume Centers and Optimal Allocation Model for Centralization of Replantations. Journal of Hand Surgery, 2021, 46, 731-739.e5.	1.6	2
148	ASO Author Reflections: Association of Community Economic Distress and Breast and Colorectal Cancer Screening, Incidence, and Mortality Rates among U.S. Counties. Annals of Surgical Oncology, 2021, , 1.	1.5	2
149	Healthcare provider self-reported observations and behaviors regarding their role in the spiritual care of cancer patients. Supportive Care in Cancer, 2021, 29, 4405-4412.	2.2	5
150	ASO Author Reflections: Optimizing End-of-Life Care for Patients Dying from Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 5423-5424.	1.5	1
151	Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Annals of Surgery, 2021, 274, e1187-e1195.	4.2	105
152	Response to the Comment on “Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis” Annals of Surgery, 2021, 274, e743.	4.2	18
153	County-level Social Vulnerability is Associated With Worse Surgical Outcomes Especially Among Minority Patients. Annals of Surgery, 2021, 274, 881-891.	4.2	103
154	Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. Journal of Clinical Medicine, 2021, 10, 104.	2.4	24
155	Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies. Cancers, 2021, 13, 5169.	3.7	18
156	Spiritual Motivations to Practice Medicine: A Survey of Cancer Care Providers. American Journal of Hospice and Palliative Medicine, 2021, , 104990912110498.	1.4	0
157	ASO Visual Abstract: Association of Community Economic Distress and Breast and Colorectal Cancer Screening, Incidence, and Mortality Rates Among U.S. Counties. Annals of Surgical Oncology, 2021, , 1.	1.5	1
158	Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma. Hepatic Medicine: Evidence and Research, 2021, Volume 13, 93-104.	2.5	2
159	A mixedâ€‘methods approach to comparing perceptions of cancer patients' and cancer care providers' religious and spiritual beliefs, behaviours, and attitudes. European Journal of Cancer Care, 2021, 30, e13390.	1.5	1
160	ASO Author Reflections: Hepatocellular Carcinoma-Related Tumor Necrosis is Associated with Worse Long-Term Outcomes. Annals of Surgical Oncology, 2021, 28, 806-807.	1.5	0
161	Characterizing Perceptions Around the Patient-Oncologist Relationship: a Qualitative Focus Group Analysis. Journal of Cancer Education, 2020, 35, 447-453.	1.3	13
162	Insurance Coverage Type Impacts Hospitalization Patterns Among Patients with Hepatopancreatic Malignancies. Journal of Gastrointestinal Surgery, 2020, 24, 1320-1329.	1.7	10

#	ARTICLE	IF	CITATIONS
163	Minimally Invasive Liver Resection for Early-Stage Hepatocellular Carcinoma: Inconsistent Outcomes from Matched or Weighted Cohorts. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 560-568.	1.7	5
164	Textbook Outcomes Among Medicare Patients Undergoing Hepatopancreatic Surgery. <i>Annals of Surgery</i> , 2020, 271, 1116-1123.	4.2	158
165	Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 552-560.	1.5	25
166	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. <i>Hpb</i> , 2020, 22, 215-223.	0.3	20
167	In-hospital Mortality Following Pancreatoduodenectomy: a Comprehensive Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1119-1126.	1.7	19
168	Effect of Surgical Margin Width on Patterns of Recurrence among Patients Undergoing R0 Hepatectomy for T1 Hepatocellular Carcinoma: An International Multi-Institutional Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1552-1560.	1.7	37
169	Trends in the Geospatial Distribution of Adult Inpatient Surgical Cancer Care Across the United States. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2127-2134.	1.7	14
170	Patient Perceptions About the Role of Religion and Spirituality During Cancer Care. <i>Journal of Religion and Health</i> , 2020, 59, 1933-1945.	1.7	20
171	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. <i>Annals of Surgical Oncology</i> , 2020, 27, 783-792.	1.5	20
172	Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-O, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. <i>Annals of Surgical Oncology</i> , 2020, 27, 866-874.	1.5	38
173	ASO Author Reflections: Use of Machine Learning to Identify Patients with Intrahepatic Cholangiocarcinoma Who Could Benefit More from Neoadjuvant Therapies. <i>Annals of Surgical Oncology</i> , 2020, 27, 1120-1121.	1.5	2
174	A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated with Resection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1110-1119.	1.5	41
175	Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. <i>American Journal of Surgery</i> , 2020, 219, 478-483.	1.8	39
176	Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium. <i>Journal of Surgical Oncology</i> , 2020, 121, 503-510.	1.7	24
177	Optimal Location for Centralization of Hospitals Performing Pancreas Resection in California. <i>JAMA Surgery</i> , 2020, 155, 261.	4.3	22
178	Hospital variation in Textbook Outcomes following curative-intent resection of hepatocellular carcinoma: an international multi-institutional analysis. <i>Hpb</i> , 2020, 22, 1305-1313.	0.3	45
179	Photodynamic therapy may provide a benefit over systemic chemotherapy among non-surgically managed patients with extrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 286-293.	1.7	7
180	CMS Hospital Compare System of Star Ratings and Surgical Outcomes Among Patients Undergoing Surgery for Cancer: Do the Ratings Matter?. <i>Annals of Surgical Oncology</i> , 2020, 27, 3138-3146.	1.5	5

#	ARTICLE	IF	CITATIONS
181	Travel to a high volume hospital to undergo resection of gallbladder cancer: does it impact quality of care and long-term outcomes?. Hpb, 2020, 22, 41-49.	0.3	14
182	How Safe Are Safety-Net Hospitals? Opportunities to Improve Outcomes for Vulnerable Patients Undergoing Hepatopancreaticobiliary Surgery. Journal of Gastrointestinal Surgery, 2020, 24, 2570-2578.	1.7	8
183	Interaction of Surgeon Volume and Nurse-to-Patient Ratio on Post-operative Outcomes of Medicare Beneficiaries Following Pancreaticoduodenectomy. Journal of Gastrointestinal Surgery, 2020, 24, 2551-2559.	1.7	13
184	Skilled nursing facility (SNF) utilization and impact of SNF star-quality ratings on outcomes following hepatectomy among Medicare beneficiaries. Hpb, 2020, 22, 109-115.	0.3	7
185	New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy, 2020, 21, 183-191.	1.8	9
186	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. Annals of Surgical Oncology, 2020, 27, 1203-1212.	1.5	21
187	ASO Author Reflections: Trends in the Number of Lymph Nodes Evaluated Following Resection of Pancreatic Neuroendocrine Tumors—An Increasing Adoption of the AJCC Guidelines?. Annals of Surgical Oncology, 2020, 27, 1213-1214.	1.5	0
188	Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients. Journal of Gastrointestinal Surgery, 2020, 24, 2756-2765.	1.7	5
189	Development and validation of a real-time mortality risk calculator before, during and after hepatectomy: an analysis of the ACS NSQIP database. Hpb, 2020, 22, 1158-1167.	0.3	2
190	Response to comments on “Impact of tumor size and nodal status on the recurrence of nonfunctional pancreatic neuroendocrine tumors ≥2cm after curative resection: a multi-institutional study of 392 cases”. Journal of Surgical Oncology, 2020, 121, 411-412.	1.7	0
191	ASO Author Reflections: Resection for Hepatocellular Carcinoma Beyond the BCLC Guidelines—How Can Machine Learning Techniques Help?. Annals of Surgical Oncology, 2020, 27, 875-876.	1.5	1
192	Preoperative continuity of care and its relationship with cost of hepatopancreatic surgery. Surgery, 2020, 168, 809-815.	1.9	4
193	ASO Author Reflections: Centralization of High-Risk Cancer Surgery and Implications for Vulnerable Communities. Annals of Surgical Oncology, 2020, 27, 844-845.	1.5	7
194	Is Patient Satisfaction Dictated by Quality of Care Among Patients Undergoing Complex Surgical Procedures for a Malignant Indication?. Annals of Surgical Oncology, 2020, 27, 3126-3135.	1.5	8
195	Textbook oncologic outcome is associated with increased overall survival after esophagectomy. Surgery, 2020, 168, 953-961.	1.9	36
196	Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Review of Anticancer Therapy, 2020, 20, 765-773.	2.4	13
197	A Novel Machine-Learning Approach to Predict Recurrence After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 5139-5147.	1.5	20
198	Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma. JAMA Surgery, 2020, 155, 823.	4.3	116

#	ARTICLE	IF	CITATIONS
199	Quality Versus Costs Related to Gastrointestinal Surgery: Disentangling the Value Proposition. Journal of Gastrointestinal Surgery, 2020, 24, 2874-2883.	1.7	14
200	ASO Author Reflections: Influence of Patient Clinical- and Treatment-Level Factors on Religious/Spiritual Preferences During Cancer Care. Annals of Surgical Oncology, 2020, 27, 753-754.	1.5	2
201	ASO Author Reflections: Development and Validation of a Novel Risk Score Using Machine-Learning Methodology to Predict Recurrence After Hepatectomy for Colorectal Liver Metastases. Annals of Surgical Oncology, 2020, 27, 5148-5149.	1.5	0
202	Clinical relevance of performing endoscopic ultrasoundâ€guided fineâ€needle biopsy for pancreatic neuroendocrine tumors less than 2â€cm. Journal of Surgical Oncology, 2020, 122, 1393-1400.	1.7	15
203	ASO Author Reflections: Patient Satisfaction and Quality of Care. Annals of Surgical Oncology, 2020, 27, 3136-3137.	1.5	2
204	Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. Annals of Surgery, 2020, 272, 574-581.	4.2	52
205	The Impact of Mental Illness on Postoperative Outcomes Among Medicare Beneficiaries. Annals of Surgery, 2020, 272, 419-425.	4.2	37
206	The association of neighborhood social vulnerability with surgical textbook outcomes among patients undergoing hepatopancreatic surgery. Surgery, 2020, 168, 868-875.	1.9	76
207	Assessing a Surgeonâ€™s Competency for High-Risk Procedures. JAMA Network Open, 2020, 3, e203888.	5.9	4
208	The Landmark Series: Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2859-2865.	1.5	16
209	ASO Author Reflections: Assessing the Outcomes of Liver Cancer Patients Undergoing Surgery Over the Last Decadeâ€”Are We Doing Better?. Annals of Surgical Oncology, 2020, 27, 3328-3329.	1.5	0
210	Outcomes of neoadjuvant chemotherapy before CRSâ€HIPEC for patients with appendiceal cancer. Journal of Surgical Oncology, 2020, 122, 388-398.	1.7	11
211	Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. Annals of Surgical Oncology, 2020, 27, 3318-3327.	1.5	59
212	ASO Author Reflections: A Nomogram to Predict Recurrence after Curative-Intent Resection for Neuroendocrine Liver Metastasis. Annals of Surgical Oncology, 2020, 27, 3727-3728.	1.5	2
213	Current Advances in Minimally Invasive Surgical Management of Perihilar Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 2143-2149.	1.7	6
214	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. Journal of Surgical Oncology, 2020, 122, 442-449.	1.7	1
215	Variation in value among hospitals performing complex cancer operations. Surgery, 2020, 168, 106-112.	1.9	9
216	A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. Annals of Surgical Oncology, 2020, 27, 5224-5232.	1.5	20

#	ARTICLE	IF	CITATIONS
217	Health expenditures and financial burden among patients with major gastrointestinal cancers relative to other common cancers in the United States. <i>Surgery</i> , 2020, 167, 985-990.	1.9	7
218	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2020, 121, 1201-1208.	1.7	23
219	Immunotherapy utilization for hepatobiliary cancer in the United States: disparities among patients with different socioeconomic status. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 13-24.	1.5	11
220	Examining healthcare inequities relative to United States safety net hospitals. <i>American Journal of Surgery</i> , 2020, 220, 525-531.	1.8	21
221	The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2888-2901.	1.5	44
222	ASO Author Reflections: Chance of Textbook Outcome following Hepatopancreatic Surgery Varies Based on Cancer Center Designation. <i>Annals of Surgical Oncology</i> , 2020, 27, 1898-1899.	1.5	1
223	ASO Author Reflections: Identification of Intrahepatic Cholangiocarcinoma Clusters Using Machine Learning Techniques: Should Patients be Treated Differently?. <i>Annals of Surgical Oncology</i> , 2020, 27, 5233-5234.	1.5	1
224	Surgical management of pancreatic neuroendocrine liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 590-600.	1.4	19
225	Recurrence beyond the Milan criteria after curative-intent resection of hepatocellular carcinoma: A novel tumor burden based prediction model. <i>Journal of Surgical Oncology</i> , 2020, 122, 955-963.	1.7	20
226	ASO Author Reflections: The Influence of Surgeon Characteristics on Patient-Centered Approaches to Treatment Decision-Making. <i>Annals of Surgical Oncology</i> , 2020, 27, 2157-2158.	1.5	0
227	Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 230, 381-391e2.	0.5	31
228	Assessing post-discharge costs of hepatopancreatic surgery: an evaluation of Medicare expenditure. <i>Surgery</i> , 2020, 167, 978-984.	1.9	10
229	Assessment of utilization efficiency using machine learning techniques: A study of heterogeneity in preoperative healthcare utilization among super-utilizers. <i>American Journal of Surgery</i> , 2020, 220, 714-720.	1.8	15
230	Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. <i>Journal of the American College of Surgeons</i> , 2020, 230, 363-370.	0.5	45
231	Assessing surgical care for esophageal cancer: patient travel patterns to reach higher volume center. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.4	12
232	Dedicated Cancer Centers are More Likely to Achieve a Textbook Outcome Following Hepatopancreatic Surgery. <i>Annals of Surgical Oncology</i> , 2020, 27, 1889-1897.	1.5	41
233	Comparing textbook outcomes among patients undergoing surgery for cancer at U. S. News & World Report ranked hospitals. <i>Journal of Surgical Oncology</i> , 2020, 121, 927-935.	1.7	33
234	Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 936-944.	1.7	56

#	ARTICLE	IF	CITATIONS
235	Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. British Journal of Surgery, 2020, 107, 854-864.	0.3	83
236	Does spiritual and religious orientation impact the clinical practice of healthcare providers?. Journal of Interprofessional Care, 2020, 34, 520-527.	1.7	7
237	Technical modifications and outcomes after Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) for primary liver malignancies: A systematic review. Surgical Oncology, 2020, 33, 70-80.	1.6	14
238	The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. Hpb, 2020, 22, 1667-1674.	0.3	37
239	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2020, 9, 1129.	2.4	83
240	Assessing Differences in Cancer Surgeon Approaches to Patient-Centered Decision-Making Using Vignette-Based Methodology. Annals of Surgical Oncology, 2020, 27, 2149-2156.	1.5	2
241	ASO Author Reflections: Recurrence Patterns and Outcomes After Resection of Hepatocellular Carcinoma Within and Beyond the Barcelona Clinic Liver Cancer Criteria. Annals of Surgical Oncology, 2020, 27, 2332-2333.	1.5	2
242	Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria. Annals of Surgical Oncology, 2020, 27, 2321-2331.	1.5	76
243	Influence of hospital teaching status on the chance to achieve a textbook outcome after hepatopancreatic surgery for cancer among Medicare beneficiaries. Surgery, 2020, 168, 92-100.	1.9	54
244	ASO Author Reflections: Minimally Invasive Surgery for Hepatocellular Carcinoma in the Setting of Portal Vein Hypertension. Annals of Surgical Oncology, 2020, 27, 3372-3373.	1.5	1
245	Tumour Burden Score: An Authentic, Easy-To-Use Prognostic Marker for Hepatocellular Carcinoma. British Journal of Surgery, 2020, 107, e626.	0.3	2
246	Rural Surgery and Status of the Rural Workplace. Surgical Clinics of North America, 2020, 100, 835-847.	1.5	21
247	A mixed-methods approach to understanding the role of religion and spirituality in healthcare provider well-being.. Psychology of Religion and Spirituality, 2020, 12, 487-493.	1.3	13
248	Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. Annals of Surgical Oncology, 2020, 27, 3717-3726.	1.5	4
249	Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. World Journal of Gastrointestinal Surgery, 2020, 12, 159-170.	1.5	7
250	Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 556-563.	4.9	26
251	ASO Author Reflections: Advances in the Multidisciplinary Management of Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2866-2867.	1.5	2
252	Liver Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 227-241.	1.6	8

#	ARTICLE	IF	CITATIONS
253	Treatment of neuroendocrine liver metastases: a patent landscape review. Pharmaceutical Patent Analyst, 2020, 9, 29-32.	1.1	0
254	Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A populationâ€based analysis. Journal of Surgical Oncology, 2019, 119, 278-287.	1.7	30
255	Prognosis and Adherence with the National Comprehensive Cancer Network Guidelines of Patients with Biliary Tract Cancers: an Analysis of the National Cancer Database. Journal of Gastrointestinal Surgery, 2019, 23, 518-528.	1.7	12
256	Hospice utilization among Medicare beneficiaries dying from pancreatic cancer. Journal of Surgical Oncology, 2019, 120, 624-631.	1.7	19
257	Discordance in prediction of prognosis among patients with intrahepatic cholangiocarcinoma: A preoperative vs postoperative perspective. Journal of Surgical Oncology, 2019, 120, 946-955.	1.7	6
258	Novel Machine Learning Approach to Identify Preoperative Risk Factors Associated With Super-Utilization of Medicare Expenditure Following Surgery. JAMA Surgery, 2019, 154, 1014.	4.3	32
259	The Impact of Dedicated Cancer Centers on Outcomes Among Medicare Beneficiaries Undergoing Liver and Pancreatic Cancer Surgery. Annals of Surgical Oncology, 2019, 26, 4083-4090.	1.5	18
260	Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A populationâ€based analysis. Cancer, 2019, 125, 3767-3775.	4.1	29
261	ASO Author Reflections: Which Patients Benefit the Most From Lymphadenectomy During Resection for Intrahepatic Cholangiocarcinoma?. Annals of Surgical Oncology, 2019, 26, 2969-2970.	1.5	3
262	Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. Surgery, 2019, 166, 983-990.	1.9	54
263	Comment on: Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer. British Journal of Surgery, 2019, 106, 1100-1101.	0.3	0
264	Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. Annals of Surgical Oncology, 2019, 26, 3693-3700.	1.5	117
265	Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. British Journal of Surgery, 2019, 106, 1228-1236.	0.3	45
266	Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multiâ€institutional analysis. Journal of Surgical Oncology, 2019, 120, 1080-1086.	1.7	18
267	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors â€2â€cm after curative resection: A multiâ€institutional study of 392 cases. Journal of Surgical Oncology, 2019, 120, 1071-1079.	1.7	47
268	Accessing surgical care for pancreaticoduodenectomy: Patient variation in travel distance and choice to bypass hospitals to reach higher volume centers. Journal of Surgical Oncology, 2019, 120, 1318-1326.	1.7	27
269	Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. Journal of Surgical Oncology, 2019, 120, 1302-1310.	1.7	20
270	Understanding the use of attachment theory applied to the patient-provider relationship in cancer care: Recommendations for future research and clinical practice. Surgical Oncology, 2019, 31, 101-110.	1.6	14

#	ARTICLE	IF	CITATIONS
271	U.S. News and World Report hospital ranking and surgical outcomes among patients undergoing surgery for cancer. <i>Journal of Surgical Oncology</i> , 2019, 120, 1327-1334.	1.7	12
272	Conditional disease-free survival after curative-intent liver resection for neuroendocrine liver metastasis. <i>Journal of Surgical Oncology</i> , 2019, 120, 1087-1095.	1.7	10
273	Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. <i>Surgery</i> , 2019, 166, 967-974.	1.9	45
274	Local referrals as a strategy for increasing value of surgical care among medicare patients undergoing liver and pancreatic surgery. <i>Hpb</i> , 2019, 21, 1552-1562.	0.3	5
275	Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1044-1054.	1.7	39
276	Impact of skilled nursing facility quality on postoperative outcomes after pancreatic surgery. <i>Surgery</i> , 2019, 166, 1-7.	1.9	23
277	Financial toxicity risk among adult patients undergoing cancer surgery in the United States: An analysis of the National Inpatient Sample. <i>Journal of Surgical Oncology</i> , 2019, 120, 397-406.	1.7	33
278	Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?. <i>Annals of Surgical Oncology</i> , 2019, 26, 2959-2968.	1.5	43
279	ASO Author Reflections: Routine Lymphadenectomy Should be Recommended Regardless of Morphologic Subtype of Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2251-2252.	1.5	3
280	ASO Author Reflections: Irreversible Electroporation for Locally Advanced Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 610-611.	1.5	0
281	ASO Author Reflections: Understanding Recurrence Patterns and Time Courses of Intrahepatic Cholangiocarcinoma After Surgery Helps in Postoperative Surveillance and Treatment. <i>Annals of Surgical Oncology</i> , 2019, 26, 2558-2559.	1.5	1
282	Outcomes After Resection of Hepatocellular Carcinoma: Intersection of Travel Distance and Hospital Volume. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1425-1434.	1.7	22
283	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2019, 154, e190571.	4.3	149
284	Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi-institutional analysis of 706 patients. <i>Journal of Surgical Oncology</i> , 2019, 120, 206-213.	1.7	39
285	A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The "emmetro-ticket" paradigm. <i>Journal of Surgical Oncology</i> , 2019, 120, 223-230.	1.7	26
286	Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis. <i>Journal of Surgical Research</i> , 2019, 241, 31-39.	1.6	9
287	Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2549-2557.	1.5	74
288	Understanding the Type of Support Offered Within the Caregiver, Family, and Spiritual/Religious Contexts of Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 56-64.	1.2	22

#	ARTICLE	IF	CITATIONS
289	Exploring the perception of survivors on the bidirectional impact between cancer and their social contexts: A mixed-methods approach. Palliative and Supportive Care, 2019, 17, 668-676.	1.0	3
290	Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 2019, 26, 1814-1823.	1.5	19
291	Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases. Hpb, 2019, 21, 1230-1239.	0.3	14
292	Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2019, 26, 1657-1668.	1.5	50
293	Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival. World Journal of Surgery, 2019, 43, 1777-1787.	1.6	126
294	Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2019, 26, 1841-1850.	1.5	51
295	Geographic Distribution of Adult Inpatient Surgery Capability in the USA. Journal of Gastrointestinal Surgery, 2019, 23, 1652-1660.	1.7	18
296	The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: Correlating the number of nodes removed with survival in 6531 patients. Journal of Surgical Oncology, 2019, 119, 1099-1107.	1.7	31
297	Variation in the cost-of-rescue among medicare patients with complications following hepatopancreatic surgery. Hpb, 2019, 21, 310-318.	0.3	22
298	Hot spotting surgical patients undergoing hepatopancreatic procedures. Hpb, 2019, 21, 765-772.	0.3	12
299	Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?. Annals of Surgical Oncology, 2019, 26, 2242-2250.	1.5	27
300	Association Between Travel Distance, Hospital Volume, and Outcomes Following Resection of Cholangiocarcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 944-952.	1.7	24
301	Patient preferences on the use of technology in cancer surveillance after curative surgery: A cross-sectional analysis. Surgery, 2019, 165, 782-788.	1.9	12
302	Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma. Hpb, 2019, 21, 981-989.	0.3	38
303	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, Publish Ahead of Print, e28-e35.	4.2	36
304	Characterizing and Assessing the Impact of Surgery on Healthcare Spending Among Medicare Enrolled Preoperative Super-utilizers. Annals of Surgery, 2019, 270, 554-563.	4.2	29
305	Understanding patient expectations around therapeutic benefits, risks, and the chance of cure. American Journal of Surgery, 2019, 217, 410-412.	1.8	7
306	A systematic review of the methods utilised to measure the relationship between cancer patients and oncologists: Implications for future research and practice. European Journal of Cancer Care, 2019, 28, e12981.	1.5	3

#	ARTICLE	IF	CITATIONS
307	Routine intensive care unit admission among patients undergoing major pancreatic surgery for cancer: No effect on failure to rescue. <i>Surgery</i> , 2019, 165, 741-746.	1.9	18
308	A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. <i>Surgery</i> , 2019, 165, 721-730.	1.9	66
309	The Association Between Patient Satisfaction and Patient-Reported Health Outcomes. <i>Journal of Patient Experience</i> , 2019, 6, 201-209.	0.9	47
310	Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 21-29.	1.7	33
311	The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 101-108.	3.1	12
312	Index versus Non-index Readmission After Hepato-Pancreato-Biliary Surgery: Where Do Patients Go to Be Readmitted?. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 702-711.	1.7	25
313	Procedure-Specific Volume and Nurse-to-Patient Ratio: Implications for Failure to Rescue Patients Following Liver Surgery. <i>World Journal of Surgery</i> , 2019, 43, 910-919.	1.6	26
314	Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Surgical Research</i> , 2019, 234, 103-109.	1.6	15
315	Reciprocity within patient-physician and patient-spouse/caregiver dyads: insights into patient-centered care. <i>Supportive Care in Cancer</i> , 2019, 27, 1237-1244.	2.2	7
316	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. <i>Surgery</i> , 2019, 165, 548-556.	1.9	39
317	Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2019, 269, 1129-1137.	4.2	74
318	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3704-3721.	3.3	107
319	Safety and oncologic outcomes of robotic liver resections: A systematic review. <i>Journal of Surgical Oncology</i> , 2018, 117, 1517-1530.	1.7	59
320	The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1140-1149.	1.5	48
321	Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. <i>Journal of Internal Medicine</i> , 2018, 283, 568-577.	6.0	78
322	Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. <i>British Journal of Surgery</i> , 2018, 105, 1210-1220.	0.3	105
323	Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. <i>British Journal of Surgery</i> , 2018, 105, 857-866.	0.3	74
324	Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2018, 117, 868-878.	1.7	36

#	ARTICLE	IF	CITATIONS
325	Association of shared decision-making on patient-reported health outcomes and healthcare utilization. American Journal of Surgery, 2018, 216, 7-12.	1.8	140
326	Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. Surgery, 2018, 163, 1114-1120.	1.9	27
327	Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-Intent Surgery: A Multi-Institutional Study from the US Extrahepatic Biliary Malignancy Consortium. World Journal of Surgery, 2018, 42, 2919-2929.	1.6	48
328	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. Journal of Gastrointestinal Surgery, 2018, 22, 859-871.	1.7	38
329	Lymphadenectomy for Intrahepatic Cholangiocarcinoma: Has Nodal Evaluation Been Increasingly Adopted by Surgeons over Time? A National Database Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 668-675.	1.7	55
330	Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. Journal of the American College of Surgeons, 2018, 226, 393-403.	0.5	37
331	The impact of the aging population and incidence of cancer on future projections of general surgical workforce needs. Surgery, 2018, 163, 553-559.	1.9	43
332	Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. World Journal of Surgery, 2018, 42, 2551-2560.	1.6	47
333	Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC. Journal of Gastrointestinal Surgery, 2018, 22, 1576-1584.	1.7	13
334	Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2018, 44, 927-938.	1.0	97
335	Impact of Post-Discharge Disposition on Risk and Causes of Readmission Following Liver and Pancreas Surgery. Journal of Gastrointestinal Surgery, 2018, 22, 1221-1229.	1.7	20
336	Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. Journal of Gastrointestinal Surgery, 2018, 22, 52-59.	1.7	92
337	The Tumor Burden Score. Annals of Surgery, 2018, 267, 132-141.	4.2	264
338	Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. Hpb, 2018, 20, 277-284.	0.3	39
339	Transplantation Versus Resection for Hilar Cholangiocarcinoma. Annals of Surgery, 2018, 267, 797-805.	4.2	137
340	Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA. World Journal of Surgery, 2018, 42, 835-840.	1.6	16
341	Early <i>versus</i> late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. British Journal of Surgery, 2018, 105, 848-856.	0.3	158
342	Updates and Critical Insights on Glissonian Approach in Liver Surgery. Journal of Gastrointestinal Surgery, 2018, 22, 154-163.	1.7	18

#	ARTICLE	IF	CITATIONS
343	Adjuvant Therapy for Biliary Tract Cancers: New Evidence to Resolve Old Questions. Journal of Oncology Practice, 2018, 14, 723-724.	2.5	8
344	Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surgery and Nutrition, 2018, 7, 270-276.	1.5	35
345	Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome. Journal of Surgical Oncology, 2018, 118, 1096-1104.	1.7	8
346	Association of <i>BRAF</i> Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surgery, 2018, 153, e180996.	4.3	151
347	The impact of a malignant diagnosis on the pattern and outcome of readmission after liver and pancreatic surgery: An analysis of the nationwide readmissions database. Journal of Surgical Oncology, 2018, 117, 1624-1637.	1.7	6
348	Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Surgical Oncology, 2018, 27, 280-288.	1.6	132
349	The Impact of Discharge Timing on Readmission Following Hepatopancreatobiliary Surgery: a Nationwide Readmission Database Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 1538-1548.	1.7	14
350	Practices and Perceptions Among Surgical Oncologists in the Perioperative Care of Obese Cancer Patients. Annals of Surgical Oncology, 2018, 25, 2513-2519.	1.5	7
351	Minimally Invasive Versus Open Primary Resection for Retroperitoneal Soft Tissue Sarcoma: A Propensity-Matched Study From the National Cancer Database. Annals of Surgical Oncology, 2018, 25, 2209-2217.	1.5	13
352	Outcomes of Surgical and Endoscopic Resection of Duodenal Neuroendocrine Tumours (NETs): a Systematic Review of the Literature. Journal of Gastrointestinal Surgery, 2018, 22, 1652-1658.	1.7	17
353	Serum tumor markers enhance the predictive power of the AJCC and LCSCJ staging systems in resectable intrahepatic cholangiocarcinoma. Hpb, 2018, 20, 956-965.	0.3	28
354	The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery, 2018, 164, 411-418.	1.9	38
355	Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Review of Gastroenterology and Hepatology, 2018, 12, 671-681.	3.0	45
356	Neuroendocrine liver metastasis: The chance to be cured after liver surgery. Journal of Surgical Oncology, 2017, 115, 687-695.	1.7	35
357	Prognostic impact of complications after resection of early stage hepatocellular carcinoma. Journal of Surgical Oncology, 2017, 115, 791-804.	1.7	53
358	Frailty as a Risk Predictor of Morbidity and Mortality Following Liver Surgery. Journal of Gastrointestinal Surgery, 2017, 21, 822-830.	1.7	65
359	Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. British Journal of Surgery, 2017, 104, 926-935.	0.3	18
360	Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology, 2017, 115, 805-811.	1.7	28

#	ARTICLE	IF	CITATIONS
361	The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients—A multi-institutional analysis. <i>Journal of Surgical Oncology</i> , 2017, 115, 312-318.	1.7	46
362	Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. <i>Surgical Oncology</i> , 2017, 26, 125-137.	1.6	99
363	Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2017, 115, 696-703.	1.7	85
364	Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis. <i>Journal of Surgical Oncology</i> , 2017, 116, 133-139.	1.7	57
365	Regret in Surgical Decision Making: A Systematic Review of Patient and Physician Perspectives. <i>World Journal of Surgery</i> , 2017, 41, 1454-1465.	1.6	87
366	Personalized treatment in patients with colorectal liver metastases. <i>Journal of Surgical Research</i> , 2017, 216, 26-29.	1.6	21
367	Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. <i>Surgery</i> , 2017, 162, 525-536.	1.9	126
368	Liver transplantation for unresectable colorectal liver metastases: A systematic review. <i>Journal of Surgical Oncology</i> , 2017, 116, 288-297.	1.7	56
369	Risk factors and prediction model for inpatient surgical site infection after major abdominal surgery. <i>Journal of Surgical Research</i> , 2017, 217, 153-159.	1.6	58
370	Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis. <i>Journal of Surgical Oncology</i> , 2017, 116, 298-306.	1.7	39
371	The prognostic utility of the “Tumor Burden Score” based on preoperative radiographic features of colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 2017, 116, 515-523.	1.7	45
372	Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis. <i>Journal of Surgical Oncology</i> , 2017, 116, 643-650.	1.7	80
373	Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1076-1085.	1.7	112
374	Effect of Background Liver Cirrhosis on Outcomes of Hepatectomy for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2017, 152, e165059.	4.3	81
375	Factors associated with decisional regret among patients undergoing major thoracic and abdominal operations. <i>Surgery</i> , 2017, 161, 1058-1066.	1.9	35
376	The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary Consortium. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2016-2024.	1.7	20
377	Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. <i>Surgical Oncology</i> , 2017, 26, 411-422.	1.6	10
378	Aspartate β -hydroxylase disrupts mitochondrial DNA stability and function in hepatocellular carcinoma. <i>Oncogenesis</i> , 2017, 6, e362-e362.	4.9	11

#	ARTICLE	IF	CITATIONS
379	Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 1085-1095.	1.7	42
380	Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. <i>Hpb</i> , 2017, 19, 901-909.	0.3	74
381	Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1821-1830.	1.7	24
382	Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2039-2047.	1.7	23
383	Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1841-1850.	1.7	65
384	Trends in the Mortality of Hepatocellular Carcinoma in the United States. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 2033-2038.	1.7	53
385	The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis. <i>Journal of Surgical Oncology</i> , 2017, 116, 841-847.	1.7	15
386	Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2017, 266, 641-649.	4.2	97
387	Hospital Volume and the Costs Associated with Surgery for Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1411-1419.	1.7	36
388	A Novel Pathology-Based Preoperative Risk Score to Predict Locoregional Residual and Distant Disease and Survival for Incidental Gallbladder Cancer: A 10-Institution Study from the U.S. Extrahepatic Biliary Malignancy Consortium. <i>Annals of Surgical Oncology</i> , 2017, 24, 1343-1350.	1.5	68
389	Evaluating Trends in the Volume-Outcomes Relationship Following Liver Surgery: Does Regionalization Benefit All Patients the Same?. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 463-471.	1.7	37
390	Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. <i>World Journal of Surgery</i> , 2017, 41, 224-231.	1.6	19
391	A Singular Hope: How the Discussion Around Cancer Surgery Sometimes Fails. <i>Annals of Surgical Oncology</i> , 2017, 24, 31-37.	1.5	25
392	Personalized treatment of patients with very early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 412-423.	3.7	119
393	KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 264-271.	1.5	68
394	Pathologic and Prognostic Implications of Incidental versus Nonincidental Gallbladder Cancer: A 10-Institution Study from the United States Extrahepatic Biliary Malignancy Consortium. <i>American Surgeon</i> , 2017, 83, 679-686.	0.8	44
395	Multimodality imaging of intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 67-78.	1.5	53
396	Staging of intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 35-43.	1.5	34

#	ARTICLE	IF	CITATIONS
397	Defining the possible therapeutic benefit of lymphadenectomy among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2016, 113, 685-691.	1.7	48
398	Impact of early postoperative platelet count on volumetric liver gain and perioperative outcomes after major liver resection. <i>British Journal of Surgery</i> , 2016, 103, 899-907.	0.3	25
399	The importance of surgical margins in primary malignancies of the liver. <i>Journal of Surgical Oncology</i> , 2016, 113, 296-303.	1.7	50
400	Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. <i>Cancer</i> , 2016, 122, 2698-2707.	4.1	53
401	Patient outcomes and provider perceptions following implementation of a standardized perioperative care pathway for open liver resection. <i>British Journal of Surgery</i> , 2016, 103, 564-571.	0.3	65
402	Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients undergoing resection of colorectal liver metastases: do CEA levels still have prognostic implications?. <i>Hpb</i> , 2016, 18, 1000-1009.	0.3	24
403	Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2610-2617.	1.5	128
404	A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1098-1105.	1.7	33
405	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. <i>Journal of the American College of Surgeons</i> , 2016, 222, 750-759e2.	0.5	61
406	Validation of a Nomogram to Predict the Risk of Perioperative Blood Transfusion for Liver Resection. <i>World Journal of Surgery</i> , 2016, 40, 2481-2489.	1.6	18
407	Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?. <i>Annals of Surgical Oncology</i> , 2016, 23, 708-713.	1.5	38
408	Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. <i>Hpb</i> , 2016, 18, 872-878.	0.3	66
409	A cross-sectional study of patient and provider perception of "cure" as a goal of cancer surgery. <i>Journal of Surgical Oncology</i> , 2016, 114, 677-683.	1.7	13
410	Clinical and morphometric parameters of frailty for prediction of mortality following hepatopancreaticobiliary surgery in the elderly. <i>British Journal of Surgery</i> , 2016, 103, e83-e92.	0.3	70
411	Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 4401-4409.	1.5	22
412	Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma. <i>Journal of the American College of Surgeons</i> , 2016, 223, 794-803.	0.5	24
413	Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1821-1829.	1.7	61
414	Cancer surgeons' attitudes and practices about discussing the chance of operative "cure". <i>Surgery</i> , 2016, 160, 1619-1627.	1.9	6

#	ARTICLE	IF	CITATIONS
415	The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. <i>Journal of Surgical Oncology</i> , 2016, 114, 803-809.	1.7	73
416	Nomogram to predict perioperative blood transfusion for hepatopancreaticobiliary and colorectal surgery. <i>British Journal of Surgery</i> , 2016, 103, 1173-1183.	0.3	16
417	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2016, 23, 2398-2408.	1.5	63
418	Stage-Specific Prognostic Effect of Race in Patients with Resectable Gastric Adenocarcinoma: An 8-Institution Study of the US Gastric Cancer Collaborative. <i>Journal of the American College of Surgeons</i> , 2016, 222, 633-643.	0.5	26
419	Impact of Chemotherapy and External-Beam Radiation Therapy on Outcomes among Patients with Resected Gallbladder Cancer: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 2998-3008.	1.5	44
420	Associations Between Patient Perceptions of Communication, Cure, and Other Patient-Related Factors Regarding Patient-Reported Quality of Care Following Surgical Resection of Lung and Colorectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 812-826.	1.7	23
421	Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. <i>Annals of Surgical Oncology</i> , 2016, 23, 3736-3743.	1.5	50
422	Financial Impact of Postoperative Complication Following Hepato-Pancreatico-Biliary Surgery for Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 1064-1070.	1.5	29
423	The relative effect of hospital and surgeon volume on failure to rescue among patients undergoing liver resection for cancer. <i>Surgery</i> , 2016, 159, 1004-1012.	1.9	83
424	Implementation Costs of an Enhanced Recovery After Surgery Program in the United States: A Financial Model and Sensitivity Analysis Based on Experiences at a Quaternary Academic Medical Center. <i>Journal of the American College of Surgeons</i> , 2016, 222, 219-225.	0.5	118
425	Association of Safety Culture with Surgical Site Infection Outcomes. <i>Journal of the American College of Surgeons</i> , 2016, 222, 122-128.	0.5	115
426	Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1225-1233.	1.5	23
427	A Systematic Review of the Factors that Patients Use to Choose their Surgeon. <i>World Journal of Surgery</i> , 2016, 40, 45-55.	1.6	76
428	A validated, risk assessment tool for predicting readmission after open ventral hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2016, 20, 119-129.	2.0	23
429	Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. <i>Annals of Surgical Oncology</i> , 2016, 23, 235-243.	1.5	195
430	Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. <i>PLoS Medicine</i> , 2016, 13, e1002006.	8.4	113
431	The impact of hospital volume and surgeon volume on perioperative outcomes of oncologic liver surgery. <i>Journal of the American College of Surgeons</i> , 2015, 221, e107.	0.5	1
432	Understanding Variation in 30-Day Surgical Readmission in the Era of Accountable Care. <i>JAMA Surgery</i> , 2015, 150, 1042.	4.3	74

#	ARTICLE	IF	CITATIONS
433	Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?. Cancer, 2015, 121, 3998-4006.	4.1	131
434	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer, 2015, 121, 3564-3573.	4.1	50
435	Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma. Journal of Surgical Oncology, 2015, 112, 164-172.	1.7	36
436	Impact of complications on long-term survival after resection of intrahepatic cholangiocarcinoma. Cancer, 2015, 121, 2730-2739.	4.1	61
437	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A seven-institution analysis of 837 patients from the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2015, 112, 195-202.	1.7	26
438	Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreato-biliary malignancies. Journal of Surgical Oncology, 2015, 111, 868-874.	1.7	52
439	Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer?. Journal of Surgical Oncology, 2015, 112, 877-882.	1.7	17
440	Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 991-998.	4.2	83
441	Early Versus Late Readmission After Surgery Among Patients With Employer-provided Health Insurance. Annals of Surgery, 2015, 262, 502-511.	4.2	53
442	Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterology Research and Practice, 2015, 2015, 1-14.	1.5	35
443	Intrahepatic Cholangiocarcinoma: expert consensus statement. Hpb, 2015, 17, 669-680.	0.3	372
444	Sarcopenia Adversely Impacts Postoperative Complications Following Resection or Transplantation in Patients with Primary Liver Tumors. Journal of Gastrointestinal Surgery, 2015, 19, 272-281.	1.7	185
445	A Nomogram to Predict Overall Survival and Disease-Free Survival After Curative Resection of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1828-1835.	1.5	62
446	Defining Post Hepatectomy Liver Insufficiency: Where do We stand?. Journal of Gastrointestinal Surgery, 2015, 19, 2079-2092.	1.7	92
447	Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. Surgery, 2015, 158, 339-348.	1.9	23
448	Quality of life after treatment of neuroendocrine liver metastasis. Journal of Surgical Research, 2015, 198, 155-164.	1.6	34
449	Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 221, 291-299.	0.5	73
450	Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surgery, 2015, 150, 722.	4.3	108

#	ARTICLE	IF	CITATIONS
451	Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 4158-4165.	1.5	86
452	Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 1581-1592.	1.7	129
453	Conditional Probability of Long-term Survival After Liver Resection for Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2015, 150, 538.	4.3	91
454	Conditional Disease-Free Survival After Surgical Resection of Gastrointestinal Stromal Tumors. <i>JAMA Surgery</i> , 2015, 150, 299.	4.3	52
455	Surgical Management of Intrahepatic Cholangiocarcinoma: Defining an Optimal Prognostic Lymph Node Stratification Schema. <i>Annals of Surgical Oncology</i> , 2015, 22, 2772-2778.	1.5	47
456	Outcomes of Gastric Cancer Resection in Octogenarians: A Multi-institutional Study of the U.S. Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 4371-4379.	1.5	26
457	The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 4020-4028.	1.5	126
458	The Relative Net Health Benefit of Liver Resection, Ablation, and Transplantation for Early Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2015, 39, 1474-1484.	1.6	37
459	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3716-3723.	1.5	83
460	Multivisceral Resection for Gastric Cancer: Results from the US Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 840-847.	1.5	32
461	Intrahepatic Cholangiocarcinoma: Prognosis of Patients Who Did Not Undergo Lymphadenectomy. <i>Journal of the American College of Surgeons</i> , 2015, 221, 1031-1040e4.	0.5	61
462	Enhanced Recovery After Surgery Protocols for Open Hepatectomy—Physiology, Immunomodulation, and Implementation. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 387-399.	1.7	62
463	Epidemiology of Hepatocellular Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 1-17.	1.5	256
464	Conditional Survival after Surgical Resection of Gastric Cancer: A Multi-Institutional Analysis of the US Gastric Cancer Collaborative. <i>Annals of Surgical Oncology</i> , 2015, 22, 557-564.	1.5	61
465	Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. , 2015, 121, 3564.		1
466	A Nomogram to Predict Disease-Free Survival After Surgical Resection of GIST. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 2123-2129.	1.7	26
467	Surveillance for hepatocellular carcinoma with ultrasound and AFP is associated with improvements in tumour detection, receipt of curative therapy and overall survival in patients with cirrhosis. <i>Evidence-Based Medicine</i> , 2014, 19, 225-226.	0.6	0
468	Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis. <i>Journal of Surgical Oncology</i> , 2014, 110, 163-170.	1.7	94

#	ARTICLE	IF	CITATIONS
469	Readmission incidence and associated factors after a hepatic resection at a major hepato-pancreatico-biliary academic centre. <i>Hpb</i> , 2014, 16, 972-978.	0.3	40
470	A Nomogram to Predict Long-term Survival After Resection for Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2014, 149, 432.	4.3	285
471	Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2014, 149, 565.	4.3	585
472	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2014, 60, 1268-1289.	3.7	1,151
473	Recurrence Patterns and Prognostic Factors in Patients with Hepatocellular Carcinoma in Noncirrhotic Liver: A Multi-Institutional Analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 147-154.	1.5	68
474	Management of Lymph Nodes During Resection of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Systematic Review. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 2136-2148.	1.7	90
475	Readmission After Surgery. <i>Advances in Surgery</i> , 2014, 48, 185-199.	1.3	84
476	The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2873-2881.	1.5	184
477	Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets. <i>Annals of Surgical Oncology</i> , 2014, 21, 3827-3834.	1.5	123
478	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. <i>Journal of the American College of Surgeons</i> , 2014, 219, 664-675.	0.5	139
479	A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample. <i>Surgery</i> , 2014, 156, 538-547.	1.9	60
480	The timing of complications impacts risk of readmission after hepatopancreatobiliary surgery. <i>Surgery</i> , 2014, 155, 945-953.	1.9	43
481	Surgical Management of Advanced Gastrointestinal Stromal Tumors: An International Multi-Institutional Analysis of 158 Patients. <i>Journal of the American College of Surgeons</i> , 2014, 219, 439-449.	0.5	28
482	Choosing a Cancer Surgeon: Analyzing Factors in Patient Decision Making Using a Best-Worst Scaling Methodology. <i>Annals of Surgical Oncology</i> , 2014, 21, 3732-3738.	1.5	46
483	Time-related changes in the prognostic significance of the total number of examined lymph nodes in node-negative pancreatic head cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 858-863.	1.7	21
484	Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 3779-3786.	1.5	134
485	Referral Patterns and Treatment Choices for Patients with Hepatocellular Carcinoma: A United States Population-Based Study. <i>Journal of the American College of Surgeons</i> , 2013, 217, 896-906.	0.5	47
486	Influence of Nonclinical Factors on Choice of Therapy for Early Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 448-456.	1.5	23

#	ARTICLE	IF	CITATIONS
487	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013, 45, 1470-1473.	21.4	564
488	Impact of Hospital Teaching Status on Length of Stay and Mortality Among Patients Undergoing Complex Hepatopancreaticobiliary Surgery in the USA. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 2114-2122.	1.7	55
489	Emerging Approaches in the Management of Patients with Neuroendocrine Liver Metastasis: Role of Liver-Directed and Systemic Therapies. <i>Journal of the American College of Surgeons</i> , 2013, 216, 123-134.	0.5	66
490	Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. <i>Surgery</i> , 2013, 154, 256-265.	1.9	25
491	Recurrence after operative management of intrahepatic cholangiocarcinoma. <i>Surgery</i> , 2013, 153, 811-818.	1.9	239
492	Provider versus patient factors impacting hospital length of stay after pancreaticoduodenectomy. <i>Surgery</i> , 2013, 154, 152-161.	1.9	51
493	Impact of complications on long-term survival after resection of colorectal liver metastases. <i>British Journal of Surgery</i> , 2013, 100, 711-718.	0.3	129
494	Trends and Patterns of Utilization in Post-treatment Surveillance Imaging Among Patients Treated for Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1774-1783.	1.7	23
495	Influence of Patient, Physician, and Hospital Factors on 30-Day Readmission Following Pancreatoduodenectomy in the United States. <i>JAMA Surgery</i> , 2013, 148, 1095.	4.3	137
496	Surgical Therapy for Early Hepatocellular Carcinoma in the Modern Era. <i>Annals of Surgery</i> , 2013, 258, 1022-1027.	4.2	59
497	Surgery for colorectal liver metastases: The evolution of determining prognosis. <i>World Journal of Gastrointestinal Oncology</i> , 2013, 5, 207.	2.0	64
498	Intrahepatic Cholangiocarcinoma Treated with Local-Regional Therapy: Quantitative Volumetric Apparent Diffusion Coefficient Maps for Assessment of Tumor Response. <i>Radiology</i> , 2012, 264, 285-294.	7.3	60
499	Patient Readmission and Mortality after Surgery for Hepato-Pancreato-Biliary Malignancies. <i>Journal of the American College of Surgeons</i> , 2012, 215, 607-615.	0.5	106
500	A Systematic Review: Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2012, 215, 820-830.	0.5	120
501	Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. <i>Surgery</i> , 2012, 152, 218-226.	1.9	103
502	Risk of Morbidity and Mortality Following Hepato-Pancreato-Biliary Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1727-1735.	1.7	227
503	Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. <i>Cancer</i> , 2012, 118, 2674-2681.	4.1	132
504	Hepatectomy for Noncolorectal Non-Neuroendocrine Metastatic Cancer: A Multi-Institutional Analysis. <i>Journal of the American College of Surgeons</i> , 2012, 214, 769-777.	0.5	119

#	ARTICLE	IF	CITATIONS
505	Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment. <i>Journal of Clinical Oncology</i> , 2011, 29, 3140-3145.	1.6	615
506	Surgery Versus Intra-arterial Therapy for Neuroendocrine Liver Metastasis: A Multicenter International Analysis. <i>Annals of Surgical Oncology</i> , 2011, 18, 3657-3665.	1.5	151
507	Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. <i>Hpb</i> , 2011, 13, 439-446.	0.3	345
508	Liver Resection for Colorectal Metastases in Presence of Extrahepatic Disease: Results from an International Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2011, 18, 1380-1388.	1.5	138
509	Variation in Lymph Node Assessment After Colon Cancer Resection: Patient, Surgeon, Pathologist, or Hospital?. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 471-479.	1.7	74
510	Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital - Mayo Clinic collaborative study. <i>Radiation Oncology</i> , 2011, 6, 126.	2.7	95
511	Stereotactic radiation treatment planning with volumetric modulated arc therapy: Impact of duodenal sparing on pancreatic tumor coverage.. <i>Journal of Clinical Oncology</i> , 2011, 29, 301-301.	1.6	0
512	Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis. <i>Annals of Surgical Oncology</i> , 2010, 17, 3129-3136.	1.5	400
513	Conditional Survival after Surgical Resection of Colorectal Liver Metastasis: An International Multi-Institutional Analysis of 949 Patients. <i>Journal of the American College of Surgeons</i> , 2010, 210, 755-764.	0.5	119
514	Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. <i>Hpb</i> , 2010, 12, 289-299.	0.3	163
515	The Volume-Outcomes Effect in Hepato-Pancreato-Biliary Surgery: Hospital Versus Surgeon Contributions and Specificity of the Relationship. <i>Journal of the American College of Surgeons</i> , 2009, 208, 528-538.	0.5	186
516	A Proposed Staging System for Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2009, 16, 14-22.	1.5	294
517	Predictors of Survival After Resection of Early Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2009, 249, 799-805.	4.2	239
518	Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis. <i>Annals of Surgical Oncology</i> , 2008, 15, 165-174.	1.5	331
519	Limitations of Claims and Registry Data in Surgical Oncology Research. <i>Annals of Surgical Oncology</i> , 2008, 15, 415-423.	1.5	209
520	Racial Disparity in Surgical Mortality after Major Hepatectomy. <i>Journal of the American College of Surgeons</i> , 2008, 207, 312-319.	0.5	53
521	Spirituality and Religion in the Care of Surgical Oncology Patients with Life-Threatening or Advanced Illnesses. <i>Annals of Surgical Oncology</i> , 2008, 15, 3048-3057.	1.5	34
522	Expanding Criteria for Resectability of Colorectal Liver Metastases. <i>Oncologist</i> , 2008, 13, 51-64.	3.7	389

#	ARTICLE	IF	CITATIONS
523	Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer, 2007, 110, 2484-2492.	4.1	153
524	Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery, 2007, 141, 610-618.	1.9	408
525	Surgical Therapy for Colorectal Metastases to the Liver. Journal of Gastrointestinal Surgery, 2007, 11, 1057-1077.	1.7	206
526	Incidence of Finding Residual Disease for Incidental Gallbladder Carcinoma: Implications for Re-resection. Journal of Gastrointestinal Surgery, 2007, 11, 1478-1487.	1.7	242
527	Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease. Annals of Surgical Oncology, 2006, 13, 712-720.	1.5	133
528	Feasibility of a Randomized Trial of Extended Lymphadenectomy for Pancreatic Cancer. Archives of Surgery, 2005, 140, 584.	2.2	86
529	Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Annals of Surgical Oncology, 2005, 12, 364-373.	1.5	226
530	Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplantation, 2005, 11, 1086-1092.	2.4	555
531	Critical Appraisal of the Clinical and Pathologic Predictors of Survival After Resection of Large Hepatocellular Carcinoma. Archives of Surgery, 2005, 140, 450.	2.2	203
532	Surgical treatment of hepatocellular carcinoma: Similar long-term results despite geographic variations. Liver Transplantation, 2004, 10, S74-S80.	2.4	35
533	Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients. Annals of Surgical Oncology, 2003, 10, 1059-1069.	1.5	284
534	ASO Author Reflections: Is Systemic Immune-Inflammation Index a Useful Biomarker After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium. Annals of Surgical Oncology, 0, , .	1.5	0
535	ASO Author Reflections: Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis. Annals of Surgical Oncology, 0, , .	1.5	0